Natera and Incyte Agree on Signatera-Guided Colorectal Cancer Trial
On November 10, 2026, Natera and Incyte entered a clinical collaboration for an interventional Phase II colorectal cancer trial. The protocol uses Natera’s Signatera test to track molecular residual disease in stage 2/3 patients after surgery and adjuvant chemotherapy, while Incyte’s experimental immune treatment INCA33890 is given to eligible patients without visible disease on scans. Signatera monitoring can continue for up to 12 months, and Natera will support trial design and patient matching.
Why it matters
The agreement gives Natera a role in identifying and enrolling patients for Incyte’s INCA33890 study, while expanding use of Signatera in a treatment-selection setting. Any commercial or clinical benefit remains dependent on enrollment and trial results.
Key facts
- 1The trial is registered as NCT07823322. clinicaltrialsarena.com
- 2Patients with stage 2/3 colorectal cancer who completed surgery and adjuvant chemotherapy may be screened for the study. finance.yahoo.com
- 3Signatera will be used as both a primary and secondary endpoint. finance.yahoo.com
- 4Patients with positive minimal residual disease results and no radiographic evidence of cancer may qualify for treatment with INCA33890. rttnews.com
- 5Signatera surveillance is planned for up to 12 months after adjuvant chemotherapy. clinicaltrialsarena.com
- 6Natera will provide trial-matching services using Signatera status and other eligibility criteria. finance.yahoo.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.